Evidence map›Paper›PMID 36765614›Full record

ReviewCancers2023

Role of FABP5 in T Cell Lipid Metabolism and Function in the Tumor Microenvironment.

Rong Jin, Jiaqing Hao, Jianyu Yu, Pingzhang Wang, Edward R Sauter, Bing Li

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 29 citations in OpenAlex.

  1. mBio · 2026
    Article
  2. Article
  3. Review
  4. Insulin Resistance and Inflammation.International journal of molecular sciences · 2026
    Review
  5. Article
  6. Article
  7. Modulating the PD-1-FABP5 axis in ILC2s to regulate adipose tissue metabolism in obesity.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  8. Article
  9. Utilization of Cannabidiol in Post-Organ-Transplant Care.International journal of molecular sciences · 2025
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Rong JinDepartment of Microbiology and Immunology, University of Louisville, Louisville, KY 40202, USA.
Jiaqing HaoDepartment of Microbiology and Immunology, University of Louisville, Louisville, KY 40202, USA.ORCID 0000-0002-2834-7255
Jianyu YuDepartment of Pathology, University of Iowa, Iowa City, IA 52242, USA.
Pingzhang WangNHC Key Laboratory of Medical Immunology, Department of Immunology, School of Basic Medical Sciences, Peking University, Beijing 100191, China.
Edward R SauterDivision of Cancer Prevention, National Institutes of Health/National Cancer Institute, Bethesda, MD 20892, USA.
Bing LiDepartment of Microbiology and Immunology, University of Louisville, Louisville, KY 40202, USA.ORCID 0000-0001-5363-7070
University of Iowa · USNational Institutes of Health · USPeking University · CNUniversity of Louisville · US

Funding

Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Michael J Goodheart · 2000 to 2026
$70.0M
Determine the role of SETDB1 in controlling lipid metabolism in obesity-associated cancerU01CA272424 · NCI · UNIVERSITY OF IOWA · PI Bing Li · 2022 to 2026
$6.0M
Prevention of Breast Cancer Development by Epidermal Fatty Acid Binding Protein (R01CA180986 · NCI · UNIVERSITY OF MINNESOTA · PI LI, BING · 2014 to 2025
$3.3M
Immunomodulatory mechanisms of E-FABP in psoriasis pathogenesisR01AI137324 · NIAID · UNIVERSITY OF LOUISVILLE · PI LI, BING · 2018 to 2022
$1.9M
NCI NIH HHS P30 CA086862NCI NIH HHS R01 CA180986NCI NIH HHS U01 CA272424NIH HHS R01AI137324, R01CA180986 and U01CA272424
6 · The paper itself

Abstract

To evade immune surveillance, tumors develop a hostile microenvironment that inhibits anti-tumor immunity. Recent immunotherapy breakthroughs that target the reinvigoration of tumor-infiltrating T lymphocytes (TIL) have led to unprecedented success in treating some cancers that are resistant to conventional therapy, suggesting that T cells play a pivotal role in anti-tumor immunity. In the hostile tumor microenvironment (TME), activated T cells are known to mainly rely on aerobic glycolysis to facilitate their proliferation and anti-tumor function. However, TILs usually exhibit an exhausted phenotype and impaired anti-tumor activity due to the limited availability of key nutrients (e.g., glucose) in the TME. Given that different T cell subsets have unique metabolic pathways which determine their effector function, this review introduces our current understanding of T cell development, activation signals and metabolic pathways. Moreover, emerging evidence suggests that fatty acid binding protein 5 (FABP5) expression in T cells regulates T cell lipid metabolism and function. We highlight how FABP5 regulates fatty acid uptake and oxidation, thus shaping the survival and function of different T cell subsets in the TME.

Indexed as

FABP5immunotherapylipid metabolismobesityT cellstumor microenvironment

Identifiers

PMID36765614
PMCPMC9913835
OpenAlexW4317738354

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.